SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration.
Overview
- Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Department of Comprehensive Radiation Oncology, Jiangxi Key Laboratory of oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, Jiangxi, China
- Department of science and education, The First People’s Hospital of Jiangxia District, Hubei University of Medicine, Shiyan, Hubei, China
- Department of Thoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
Abstract
Introduction: Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis, limited therapeutic options, and a highly immunosuppressive microenvironment. This study investigated the clinical significance and biological role of SLC10A3 in GBM progression and immune evasion.
Methods: Bulk transcriptomic data from TCGA and CGGA cohorts were analyzed to assess SLC10A3 expression and prognostic value. Functional enrichment, single-cell RNA sequencing, and cell–cell communication analyses were performed to explore SLC10A3-related pathways and cellular distribution. In vitro and in vivo experiments were conducted to evaluate the effects of SLC10A3 knockdown on GBM malignant phenotypes and macrophage recruitment.
Results: SLC10A3 was significantly overexpressed in GBM and associated with poor prognosis. Enrichment analyses linked SLC10A3 to PI3K-Akt, NF-κB, HIF-1 signaling, macrophage infiltration, and T-cell suppression. Single-cell analysis showed SLC10A3 enrichment in tumor-associated astrocytes and macrophages, with enhanced astrocyte–macrophage crosstalk through MIF, MDK, and extracellular matrix remodeling pathways. SLC10A3 knockdown inhibited GBM cell proliferation, migration, and invasion, induced cell cycle arrest and apoptosis, reduced M2 macrophage migration, and suppressed xenograft tumor growth.
Discussion: SLC10A3 may promote GBM aggressiveness and immune evasion by regulating malignant phenotypes and macrophage-associated immunosuppression, suggesting its potential as a therapeutic target for GBM.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data, not to its authors' code: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE182109, at NCBI GEO; found in the text, “Bulk transcriptome and single-cell data…”
Other data links
- ncbi.nlm.nih.gov/
geo , NCBI; found in the text, “Bulk transcriptome and single-cell data…”
Data availability statement
The original contributions presented in the study are included in the article/
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 28 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 8 authors, 6 keywords, 42 references.
Cite
This paper
Chen, S., Qin, D., Lin, H., Ding, T., Liu, W., Yan, Z., Wang, L., & Kou, B. (2026). SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration. Frontiers in oncology, 16, 1742452. https://
BibTeX
@article{chen2026slc10a3
author = {Chen, Shuhui and Qin, Daogang and Lin, Hanyang and Ding, Taohui and Liu, Wei and Yan, Ziqi and Wang, Lingting and Kou, Bo},
title = {{SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration}},
journal = {Frontiers in oncology},
year = {2026},
month = may,
volume = {16},
pages = {1742452},
publisher = {Frontiers Media SA},
issn = {2234-943X},
doi = {10.3389/
url = {https://
pmid = {42211491},
pmcid = {PMC13212135}
}
RIS
TY - JOUR
AU - Chen, Shuhui
AU - Qin, Daogang
AU - Lin, Hanyang
AU - Ding, Taohui
AU - Liu, Wei
AU - Yan, Ziqi
AU - Wang, Lingting
AU - Kou, Bo
TI - SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration
T2 - Frontiers in oncology
J2 - Front Oncol
PY - 2026
DA - 2026/
VL - 16
SP - 1742452
SN - 2234-943X
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration",
"container-title": "Frontiers in oncology",
"author": [
{
"family": "Chen",
"given": "Shuhui"
},
{
"family": "Qin",
"given": "Daogang"
},
{
"family": "Lin",
"given": "Hanyang"
},
{
"family": "Ding",
"given": "Taohui"
},
{
"family": "Liu",
"given": "Wei"
},
{
"family": "Yan",
"given": "Ziqi"
},
{
"family": "Wang",
"given": "Lingting"
},
{
"family": "Kou",
"given": "Bo"
}
],
"container-title-short":
"volume": "16",
"page": "1742452",
"DOI": "10.3389/
"PMID": "42211491",
"PMCID": "PMC13212135",
"ISSN": "2234-943X",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
13
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1016/j.isci.2026.115982 [code]
- Multi-omics profiling-derived signature links cellular ecosystem to glioblastoma prognosis.Journal: iScienceIn common: NCBI GEO GSE182109, genetics / omics, other condition, 6 references
- [2] doi:10.3390/cancers18132092
- TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activat
ed Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study. Journal: CancersIn common: genetics / omics, other condition, 5 references - [3] doi:10.3389/fimmu.2026.1780159
- The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma.Journal: Frontiers in immunologyIn common: NCBI GEO GSE182109, genetics / omics, other condition
- [4] doi:10.32604/or.2026.079221
- Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target.Journal: Oncology researchIn common: genetics / omics, other condition, 3 references
- [5] doi:10.1016/j.isci.2026.115875
- Role of NR2F2-mediated reprogramming of endothelial cells in glioblastoma progression.Journal: iScienceIn common: genetics / omics, other condition, 3 references
- [6] doi:10.1111/jcmm.71154
- Mitophagy-Oxidative Stress Molecular Subtypes Define an Immunosuppressive Ecosystem and Vulnerabilities in Glioblastoma.Journal: Journal of cellular and molecular medicineIn common: genetics / omics, other condition, 3 references
- [7] doi:10.3390/ijms27167240
- 1-Piperidine Propionic Acid Inhibits PAR2/
SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness. Journal: International journal of molecular sciencesIn common: other condition, 3 references - [8] doi:10.3390/biology15080633
- Development and Validation of a Toxoplasma Infection-Associated Risk Model for Prognostic Stratification and Treatment Guidance in Glioma.Journal: BiologyIn common: clinical / translational, other condition, 3 references
- [9] doi:10.1038/s41586-026-10612-6 [code]
- Acquired genetic and cell-state changes in IDH-mutant glioma progression.Journal: NatureIn common: other condition, 3 references
- [10] doi:10.1016/j.cell.2026.05.047 [code]
- An emergent disease-associated motor neuron state precedes cell death in ALS.Journal: CellIn common: genetics / omics, other condition, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.